Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes
Jun‐Sing Wang(National Yang Ming Chiao Tung University), Wayne Huey‐Herng Sheu(National Yang Ming Chiao Tung University), Cheng-Lin Tsai(Tungs' Taichung MetroHarbor Hospital), Wei‐Shiung Yang(National Taiwan University), Yi-Jen Hung(Tri-Service General Hospital), Yung-Chuan Lu(E-Da Hospital), Ting-I Lee(Taipei Medical University Hospital), Ya-Chun Hsiao(Mackay Memorial Hospital)
Cited by 9
Related Papers
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
|The Lancet|2019|3.1k
Weight Reduction Increases Plasma Levels of an Adipose-Derived Anti-Inflammatory Protein, Adiponectin
|The Journal of Clinical Endocrinology & Metabolism|2001|1.2k
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis
|The Lancet Neurology|2008|726